Keywords
gynecological cancer
cancer
antihypertensives
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the process of identification, pharmacological management and clinical implications of systemic arterial hypertension (SAH) in oncology patients during hospital stay. Methods: Retrospective, quantitative study, carried out over three months in a hospital specializing in gynecological tumors. Epidemiological and clinical data were collected from medical records. Results: 417 hospitalizations were analyzed, including patients with SAH (47.96%) and without SAH (52.04%). The comorbidity was identified mainly by pharmacists (76%) and the classes of antihypertensives most used for management were: diuretics (26.30%), angiotensin II receptor antagonists (21.85%) and angiotensin-converting enzyme inhibitors. angiotensin (18.89%). Among hypertensive patients, 75.32% had systolic blood pressure ≥ 150 mmHg during hospital stay. Of the hospitalizations, 55.64% were for surgical procedures, 19.40% of which were cancelled. In the hypertensive group, 25.20% of surgeries were canceled due to lack of clinical conditions, a reason not observed among patients without SAH. Only 15.5% of hypertensive patients underwent antineoplastic treatment prior to hospitalization, indicating that SAH was not triggered by chemotherapy. Conclusion: The prevalence of SAH in hospitalized patients with gynecological cancer is high. The clinical pharmacist is essential to optimize the identification and treatment of this comorbidity, minimizing the negative impacts of decompensated hypertension.
References
COHEN JB, et al. Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management. JACC: Cardio Oncology. 2019; 1(2): 238–51.
CURIGLIANO G, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020; 31(2): 171–90.
DA COSTA NEGRÃO SM, et al. Avaliação da prática de enfermagem na segurança do paciente oncológico. Enfermagem em Foco. 2020; 21;10(4): 136-142.
FRAEMAN KH, et al. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013; 2013:379252.
GEWEHR DM, et al. Adesão ao tratamento farmacológico da hipertensão arterial na Atenção Primária à Saúde. Saúde debate. 2018; 42(116): 179–90.
HAJJAR LA, et al. Diretriz Brasileira de Cardio-oncologia – 2020. Arquivos Brasileiros de Cardiologia. 2020; 115(5): 1006–43.
HARRISON DG, et al. Inflammation, immunity, and hypertension. Hypertension. 2011; 57(2): 132-140.
HEIJNEN BF, et al. Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Hypertension Research. 2014; 37(2): 100-109.
Instituto Nacional de Câncer. ESTIMATIVA 2023: incidência de câncer no Brasil / Instituto Nacional de Câncer. – Rio de Janeiro: INCA, 2022.
IZZEDINE H, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Annals of oncology. 2009; 20(5): 807–15.
JAIN M e TOWNSEND RR. Chemotherapy agents and hypertension: A focus on angiogenesis blockade. Current hypertension reports. 2007; 9(4): 320–8.
JIANG Y, et al. Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs? Frontiers in Pharmacology. 2023; 4;14:1143361.
KURIAKOSE RK, et al. Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxidative Medicine and Cellular Longevity. 2016; 2016: 1–9.
LI PC, et al. Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study. BMC Cancer. 2022; 22(1):430.
MACHADO LPM e GODOY H. Hipertensão arterial no tratamento do câncer. Revista da Sociedade de Cardiologia do Estado de São Paulo. 2017; 27(4):290–3.
MANTOVANI A, et al. Cancer-related inflammation. Nature. 2008; 454(7203) :436–44.
MC MENAMIN ÚC, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012; 23(2): 221-230.
MENDIS S, et al. Global Atlas on cardiovascular disease prevention and control. Geneva: World Health Organization In Collaboration With The World Heart Federation And The World Stroke Organization; 2011.
MENEZES T de C, et al. Prevalência, tratamento e controle da hipertensão arterial com método diferenciado de busca ativa. Cad saúde colet [Internet]. 2020; 28(3): 325–33.
MOTA CJF, et al. Conciliação medicamentosa em unidade de clínica médica como estratégia para Segurança do Paciente em um hospital universitário. Research, Society and Development. 2022; 11(10): e568111032128.
NEVES JA, et al. Biomarcadores de função endotelial em doenças cardiovasculares: hipertensão. J Vasc Bras. 2016; 15(3): 224–33.
NOER MC, et al. A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients. Gynecol Oncol. 2016; 141(3): 471-478.
PAI K, et al. The Utility of Comorbidity Indices in Assessing Head and Neck Surgery Outcomes: A Systematic Review. Laryngoscope. 2022; 132(7): 1388-1402.
ROTH GA, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1736–88.
SABLINA AA, et al. The antioxidant function of the p53 tumor suppressor. Nature Medicine. 2005; 11(12): 1306–13.
SALIMENA AMO, et al. Mulheres portadoras de câncer de útero: percepção da assistência de enfermagem. Revista de Enfermagem do Centro-Oeste Mineiro. 2014; 4(1): 909-920.
SARFATI D, et al. The impact of comorbidity on cancer and its treatment. CA: A Cancer Journal for Clinicians. 2016; 66(4): 337–50.
SOUSA ALL, et al. Hypertension Prevalence, Treatment and Control in Older Adults in a Brazilian Capital City. Arq Bras Cardiol. 2019; 112(3): 271–8.
VAN DORST DCH, et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research. 2021; 128(7): 1040–61.
VERAS RP. Modelo assistencial contemporâneo para os idosos: uma necessidade premente. Rev bras geriatr gerontol. 2022; 25(3):e230065.
VIGITEL, Brasil, Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Secretaria de Gestão Estratégica e Participativa. Vigitel Brasil 2017 vigilância de fatores e risco e proteção para doenças crônicas por inquérito telefônico. Brasília Ministério da Saúde; 2018.
YANG F, et al. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020; 92: 2067–1073.
YEH ETH e BICKFORD CL. Cardiovascular Complications of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and Management. Journal of the American College of Cardiology. 2009; 53(24): 2231–47.